CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Niklas Klümper; Damian J Ralser; Romina Zarbl; Katrin Schlack; Andres Jan Schrader; Marc Rehlinghaus; Michèle J Hoffmann; Günter Niegisch; Annemarie Uhlig; Lutz Trojan; Julie Steinestel; Konrad Steinestel; Ralph M Wirtz; Danijel Sikic; Markus Eckstein; Glen Kristiansen; Marieta Toma; Michael Hölzel; Manuel Ritter; Sebastian Strieth; Jörg Ellinger; Dimo Dietrich

doi:10.1136/jitc-2021-002949

Citation Tools

PDF

XML

Immunotherapy biomarkers

Original research

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Klümper N, Ralser DJ, Zarbl R, et al

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Journal for ImmunoTherapy of Cancer 2021;9:e002949. doi: 10.1136/jitc-2021-002949

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password